Cell Signaling Technology

Phospho-Stat3 (Ser727) (D4X3C) Rabbit Monoclonal Antibody (InTraSeq™ 3' Conjugate 3031)

#34774 · $434

9
Citing papers
765
Combined citations
Supplier page Find this product

Research areas

Glycogen Storage Diseases and Myoclonus4Genetics and Neurodevelopmental Disorders3CAR-T cell therapy research2Neurological disorders and treatments2Virus-based gene therapy research2HIV Research and Treatment1Circadian rhythm and melatonin1interferon and immune responses1

Papers citing this product

1
HIV-1 Vpu Neutralizes the Antiviral Factor Tetherin/BST-2 by Binding It and Directing Its Beta-TrCP2-Dependent Degradation
PLoS Pathogens·2009·300 cit.·DOI
2
Laforin, the most common protein mutated in Lafora disease, regulates autophagy
Human Molecular Genetics·2010·179 cit.·DOI
3
Abnormal Metabolism of Glycogen Phosphate as a Cause for Lafora Disease
Journal of Biological Chemistry·2008·170 cit.·DOI
4
Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
Molecular Therapy — Oncolytics·2020·32 cit.·DOI
5
Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy
Human Molecular Genetics·2008·32 cit.·DOI
6
Artificial gravity partially protects space-induced neurological deficits in Drosophila melanogaster
Cell Reports·2022·25 cit.·DOI
7
Engineered cell-based therapies in ex vivo ready-made CellDex capsules have therapeutic efficacy in solid tumors
Biomedicine & Pharmacotherapy·2023·16 cit.·DOI
8
Proteomic changes in the hippocampus of large mammals after total-body low dose radiation
PLoS ONE·2024·6 cit.·DOI
9
Neuromuscular junction dysfunction in Lafora disease
Disease Models & Mechanisms·2024·5 cit.·DOI

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.

Your email is never shown publicly.